NCT03060447 - Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

February 13, 2020

Study Completion Date

February 13, 2020

Conditions

HIV-1 Infection

Interventions

DRUG

Vesatolimod

Tablets Administered orally

DRUG

Placebo

Tablets Administered orally

DRUG

ART

ART regimens administered in accordance with their prescribing information. The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.

Trial Locations (6)

32803

Orlando Immunology Center, Orlando

34982

Midway Immunology & Research Center, Ft. Pierce

78705

Central Texas Clinical Research, Austin

90069

Mills Clinical Research, Los Angeles

94110

Zuckerberg San Francisco General, San Francisco

98104

Peter Shalit, MD, Seattle